Suzhou Wujiang
Fermentation capacity. Completed in 2016, the facility manufactures toripalimab for international commercial supply.
Global Presence
Our Wujiang and Lingang sites connect biologics process development with supply for clinical trials and commercial markets.

The two operating sites have a disclosed fermentation capacity of 46,500 L in total.
Fermentation capacity. Completed in 2016, the facility manufactures toripalimab for international commercial supply.
Phase I fermentation capacity. The site produces commercial medicines and investigational material for clinical studies.
Lingang expansion plan. In its May 2026 disclosure, the company outlined a further 120,000 L of capacity for the Phase II expansion and redevelopment project.
Teams develop manufacturing processes, optimize production conditions and support technology transfer.
Both sites support manufacturing. Wujiang supplies toripalimab for overseas markets. Lingang also produces clinical trial material.
Quality systems govern manufacturing and testing. Lingang obtained GMP certification in May 2022.